SEC Form 4 · accession 0001179110-17-014415
Kala Pharmaceuticals, Inc. · KALA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Bazemore
Officer — Chief Operating Officer
Period of report
Nov 20, 2017
Accepted (ET)
Nov 21, 2017 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479419
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $19.60 | Nov 20, 2017 | A | 172,000 | A | — | Nov 19, 2027 | Common Stock | 172,000 | 172,000 | D |
Explanation of responses
- F1This option was granted on November 20, 2017 and vests over four years, with 25% of the shares underlying the option vesting on November 20, 2018, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.